Pharmacia & Upjohn AB v CSL Limited

Link copied
Case Copied 24 min read

OFFICIAL NOTICE

DECISION OF A DELEGATE OF THE COMMISSIONER OF PATENTS

Application  :          No. 682274 in the name of Pharmacia & Upjohn AB

Title:          Filtration

Action:          Opposition under section 59 by CSL limited

Decision:          Issued            .

Abstract

Opposition succeeds and patent application is refused.

While the claims are novel based on the prior art raised by the opponent, none of the claims involve an inventive step in light of the common general knowledge alone or in combination with a particular US patent specification.  In trying to improve viral filtration, the skilled worker would be directly led to try different ways of improving protein recovery by altering parameters known to affect the recovery of protein.  This routine optimisation would include increasing the salt concentration within the range claimed for ultrafiltration membranes.  Further, because dedicated viral filters only differ in fine structure to ultrafiltration membranes, the principles involved in ultrafiltration could be extrapolated to the new filters.  Therefore, it would also be routine for a skilled worker using dedicated viral filters to increase salt to within the range claimed to try to improve viral filtration.

PATENTS ACT 1990

DECISION OF A DELEGATE OF THE COMMISSIONER OF PATENTS

Re:Patent Application No. 682274 by Pharmacia & Upjohn AB and Opposition under section 59 by CSL Limited

BACKGROUND

Australian application 682274 was filed under the provisions of the PCT on 25 June 1995 by Pharmacia AB.  It claimed priority from two Swedish basic applications, 9402254-8 and 9500724-1, filed on 23 June 1994 and 24 February 1995 respectively.  A change of applicant name to Pharmacia & Upjohn AB (Pharmacia) was subsequently made under the PCT rules and recorded in Australia on 4 November 1996.

The Australian application was advertised accepted on 25 September 1997 and on 31 December 1997, a notice of opposition was filed by CSL Limited (CSL).  Evidence was completed on 16 November 1999 and the matter was set for hearing in Melbourne on 21 February 2000.

Amendments were proposed to the accepted specification on 31 March 1999 and these were subsequently advertised allowed on 7 October 1999.  The hearing was therefore based on the specification as amended after acceptance.

The applicant was represented by Mr John Slattery patent attorney of Davies Collison Cave, Melbourne and the opponent was represented by Drs Jenny Petering and Bill Pickering, patent attorneys of FB Rice & Co, Melbourne.  Also attending the hearing were John Cox and Peter Turvey from the opponent company.

SPECIFICATION

The specification discloses and claims a method for preventing viral contamination of blood macromolecular products (such as gammaglobulin, albumin and factor IX) which are intended for medical use in human beings.

A number of prior art methods for virus removal were discussed.  The closest prior art method to the current invention involved passing biological fluid containing a pharmaceutical product through an ultrafiltration membrane.  The membrane retained the virus but permitted passage of the pharmaceutical product.  The specification discussed two prior patent specifications (US 4, 473,494 and EP 307373).  Both patent specifications…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Pharmacia & Upjohn AB v CSL Limited and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2000] APO 58
Decision Date

CaseChat Overview and Summary

Pharmacia & Upjohn AB applied for a patent for a method of preventing viral contamination of blood macromolecular products, which was opposed by CSL Limited. The dispute centred around the novelty and inventive step of the patent claims, as well as the patentable subject matter under the Patents Act 1990. The court found that while the claims were novel, they did not involve an inventive step in light of the common general knowledge alone or in combination with a particular US patent specification. The skilled worker would be directly led to try different ways of improving protein recovery by altering parameters known to affect the recovery of protein, such as increasing the salt concentration within the range claimed for ultrafiltration membranes. Additionally, because dedicated viral filters only differ in fine structure to ultrafiltration membranes, the principles involved in ultrafiltration could be extrapolated to the new filters, making it routine for a skilled worker using dedicated viral filters to increase salt to within the range claimed to try to improve viral filtration. Consequently, the court found that none of the claims, as currently drafted or if limited to the dedicated viral filters, were inventive in light of the common general knowledge. The court also refused to consider the opponent's arguments under the ground of manner of manufacture, as they were essentially the same as the arguments raised and considered under the ground of inventive step. The court concluded that there was no patentable subject matter in the specification and therefore refused the patent application. Costs were awarded to the opponent as they were successful in their opposition.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.